6667. King's Phylogene powder. (F.D.C. No. 45840. S. No. 31-822 R.)

QUANTITY: 187 btls. at Montgomery, Ala.

SHIPPED: 12-20-60, from Greenville, S.C., by Libby, Edwards & Brown, Inc.

LABEL IN PART: "King's Phylogene Powder 6 Ounces Ingredients: Potassium Alum - Lactose - Zinc Sulfocarbolate and Thymol. Directions: * * * As a Douche * * * Distributed By: King Pharmaceutical Co., Inc., P.O. Box 1925, Montgomery, Ala. 6012089."

LIBELED: 6-15-61, M. Dist. Ala.

CHARGE: 502(f)(2)—when shipped, the labeling of the article failed to bear a warning against use more than twice weekly unless directed by a physician.

DISPOSITION: 6-23-61. Consent—claimed by King Pharmaceutical Co., Inc., and relabeled.

6668. Electronic Magnetic device. (F.D.C. No. 45921. S. No. 57-799 R.)

QUANTITY: 1 device at St. Petersburg, Fla.

SHIPPED: 4-29-60, from Tiffin, Ohio, by L. L. Roby Mfg. Co.

LABEL IN PART: "Electronic Magnetic Model G."

RESULTS OF INVESTIGATION: Examination indicated that the article was a suitcase-type unit which, on opening, displayed a control panel and detector plates. The control panel contained an array of switches, dials, push buttons, electrode terminals, and indicator lights. Electronic components within the case formed a power supply, oscillator, and amplifier for the detection and/or operation of hertzian waves.

LIBELED: 6-2-61, S. Dist. Fla.

CHARGE: 502(b)(1)—when shipped and while held for sale, the device failed to bear a label containing the name and place of business of the manufacturer, packer, or distributor; and 502(f)(1)—the labeling of the article failed to bear adequate directions for use and it was not feasible to devise any directions for use because the article was worthless for any medical purposes.

DISPOSITION: 7-10-61. Default—delivered to the Food and Drug Administration.

DRUGS AND DEVICES ACTIONABLE BECAUSE OF DEVIATION FROM OFFICIAL OR OWN STANDARDS

6669. Menodol tablets. (F.D.C. No. 45594. S. No. 35-880 R.)

QUANTITY: 9 cases, each containing 24 50-tablet btls., at Santurce, P.R.

SHIPPED: 10-3-60, from New York, N.Y., by Darro Pharmacal Co., Inc.

LABEL IN PART: (Btl.) "Menodol Improved Each Menodol Tablet Contains: Mephenesin * * * 250 mg. Sodium Salicylate 200 mg. Sodium Gentisate 100 mg. * * * Darro Pharmacal Co., Inc., New York, N.Y. Distributors."

RESULTS OF INVESTIGATION: Analyses showed that the article contained mephenesin, 37 percent; sodium salicylate, 37 percent; and sodium gentisate, 49 percent, of the labeled amount.

LIBELED: 3-24-61, Dist. P.R.

CHARGE: 501(c)—when shipped, the strength and quality of the article fell below that which it purported to possess; and 502(a)—the label statements "Each Menodol Tablet Contains: Mephenesin * * * 250 mg. Sodium Salicylate 200 mg. Sodium Gentisate 100 mg." were false and misleading as

applied to the article which contained less than the declared amounts of such ingredients.

DISPOSITION: 5–29–61. Default—destruction.

6670. Imitation drugs. (F.D.C. No. 45762. S. Nos. 1–549/52 R, 1–554/5 R.)

QUANTITY: 1,700 tablets represented as Dexedrine Sulfate; 1,480 tablets represented as Dexamyl; and 250 tablets represented as Diuril, at Decatur, Ga., in possession of McKinney's Apothecary.

SHIPPED: On unknown dates, from Houston, Tex.

LIBELED: 5–2–61, N. Dist. Ga.

CHARGE: 501(d)(2)—while held for sale, imitation Dexedrine Sulfate, Dexamyl, and Diuril tablets had been substituted for Dexedrine Sulfate, Dexamyl, and Diuril tablets, respectively; 502(a)—the label statements "Dexedrine Tablets 5 mg.," * * * 1000 tablets 5 mg. each Dexedrine Sulfate Smith Kline & French Laboratories * * * T 5265," "Dexedrine tabs * * * Amp. 425 * * * AXDP M," "Dexamyl Tablets 5 mg.," "Diuril 0.5 * * * 1000 tablets * * * Diuril chlorothiazide * * * Merck Sharp & Dohme Division of Merck & Co. * * *," and "Dexamyl Tabs * * * Amt. 425 * * * AERN M" were false and misleading as applied to products which were imitations of such drugs; and 502(i)—the articles were (2) imitations of other drugs and (3) offered for sale under the names of other drugs.

DISPOSITION: 6–19–61. Default—delivered to the Food and Drug Administration.

6671. Imitation Meticorten tablets. (F.D.C. No. 45766. S. No. 59–207 R.)

QUANTITY: 1 btl. containing a total of about 600 tablets at Chicago, Ill., in possession of Accurate Wholesale Drug Corp.

SHIPPED: On an unknown date, from outside the State of Illinois.

LABEL IN PART: (Btl.) "Schering 1,000 Tablets Meticorten (Prednisone) 5 mg. * * * Schering Corporation, Bloomfield, New Jersey, 2146011."

LIBELED: 5–3–61, N. Dist. Ill.

CHARGE: 501(d)(2)—while held for sale, an imitation of Meticorten had been substituted in part for Meticorten; 502(a)—the name "Schering Meticorten (Prednisone)" was false and misleading as applied to a product consisting in part of tablets that were not Schering Meticorten tablets; 502(i)(2)—the article was an imitation of another drug; and 502(i)(3)—the article was offered for sale under the name of another drug, namely, Schering Meticorten tablets.

DISPOSITION: 5–25–61. Default—destruction.

6672. Imitation Serpasil tablets and imitation Equanil tablets. (F.D.C. No. 45763. S. Nos. 26–890 R, 26–893 R.)

QUANTITY: 1 900-tablet btl. of *imitation Serpasil tablets*, and 4 btls. containing a total of about 229 *imitation Equanil tablets*, at Los Angeles, Calif., in possession of Yeilding's Pharmacy.

SHIPPED: During the latter part of 1960 and prior to 4–5–61, from Houston, Tex.

LIBELED: 5–2–61, S. Dist. Calif.

CHARGE: 501(d)(2)—while held for sale, *imitation Serpasil tablets* and *imitation Equanil tablets* had been substituted for Serpasil tablets and Equanil